Abstract
Background The escalation of colistin resistance, due to transferable mcr-genes, threatens public and animal health as there are limited therapeutic options. Given that colistin is a last-line antibiotic, there is a need to contain the spread of its resistance to conserve its efficacy. Herein, current and emerging colistin resistance diagnostics are described to inform faster clinical diagnostic choices.
Methods A literature search in Pubmed, between 2016 and 2020, was performed. English articles evaluating colistin resistance methods/diagnostics were included.
Results Screening resulted in the inclusion of 89 journal articles. Current colistin resistance diagnostics are either phenotypic or molecular. Broth microdilution (BMD) is currently the only golden standard for determining colistin MIC values. However, other methods have been developed to overcome the challenges associated with the BMD.
Phenotypic methods comprise agar-based methods i.e. ChromAgar Col-APSE, SuperPolymyxin, ChromID Colistin R etc., MIC-determiners i.e. Microscan, BD Phoenix, Sensitest colistin, Sensititre, Micronaut etc., MCR-detectors i.e. lateral flow immunoassay (LFI), chelator based assays i.e. EDTA- and DPA-based tests as well as biochemical colorimetric tests i.e. Rapid Polymyxin NP test, Rapid ResaPolymyxin NP test etc. Molecular methods only characterize mobile colistin resistance; they include PCR, LAMP, whole-genome sequencing (WGS) etc.
Conclusion Considering the efficiency (sensitivity, specificity, turnaround time) of the Rapid ResaPolymyxin NP test, it is recommended for the initial screening of colistin-resistant isolates. This can be followed by chelator-based tests or the LFI for the rapid screening of mcr-genes. However molecular assays such as LAMP, PCR may be considered for use in well-equipped clinical laboratories.
Tweet “Colistin-resistance is a global threat to bacterial infections’ management. Being a last-resort antibiotic for treating of MDR Gram-negative infections, it is important to establish an efficient diagnostic method for routine use in clinical microbiology laboratories. Herein, current & emerging diagnostics for detecting colistin resistance are described to inform clinical diagnostic options.”
Author summary/highlights/importance
The spread of colistin resistance is rapidly increasing, threatening public and veterinary healthcare.
As one of the last-line antibiotics, colistin has to be conserved by containing the spread of colistin resistance.
Detecting colistin resistance relies on determining colistin MIC values by standard broth microdilution, which is labour-intensive with longer turnaround time (TAT).
Other colistin resistance diagnostics have been developed to augment or replace the broth microdilution with faster TAT.
Based on their respective sensitivities, specificities, TAT, skill, and cost, selected phenotypic and molecular assays are recommended for laboratories, according to their financial strengths, to enhance colistin resistance surveillance and control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version has been revised to remove certain literary errors, clarification of the nature of the Sensititre test, and better formatting of the Table
Data Availability
All data are available in the manuscript